SEATTLE, Feb. 7 /PRNewswire/ -- Koronis Pharmaceuticals, Inc., a biotechnology company focused on the development of antiviral therapeutics, today announced the appointment of David Drajeske as Director of Business Development.
Drajeske brings more than a decade of business development experience in the life sciences industry. He formerly served as Vice President of Business Development for Helix BioMedix, a publicly traded biotechnology company, from 2004 to 2006. While at Helix, Drajeske was involved in the initiation and negotiation of multiple development collaborations. Prior to Helix, Drajeske served as Manager of Business Development for Immunex Corporation. He has also served as Senior Manager, Business Development and Alliance Management for Thermogen, Inc. and Medichem Life Sciences. Drajeske received an M.S. in Biotechnology from Northwestern University's Kellogg Center for Biotechnology and a B.S. in chemical engineering from Purdue University.
"David will be instrumental in our outreach activities aimed at educating potential partners about Koronis' innovative Viral Decay Acceleration therapeutics," said Donald Elmer, Chairman and interim Chief Executive Officer of Koronis. "His business development experience will be an asset to our Company."
Koronis Pharmaceuticals, Inc. is a privately held biotechnology company developing anti-viral therapeutics based on a novel mechanism, Viral Decay Acceleration (VDA). The Company's lead product candidate, KP-1461 for the treatment of human immunodeficiency virus (HIV), is currently being evaluated in a Phase 2 trial. In addition to KP-1461, the Company has products in development for the treatment of hepatitis C and RSV. For more information on Koronis, please visit http://www.koronispharma.com.
CONTACT: Julie Rathbun of Rathbun Communications, Inc., +1-206-769-9219,
email@example.com, for Koronis Pharmaceuticals, Inc.
Web site: http://www.koronispharma.com/